iBio Inc (IBIO)

NASD · Healthcare · Biotechnology · USA

iBio Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

iBio is a clinical-stage biotechnology company developing precision antibodies using artificial intelligence for obesity, cardiometabolic, and cardiopulmonary diseases. The company leverages its AI Drug Discovery Platform to identify novel biologics targeting unmet medical needs. iBio has advanced IBIO-600 into human clinical trials and is developing additional therapeutic candidates in preclinical stages.

From its FY2026 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the iBio Inc stock.

Our verdict on IBIO

Undervalued: intrinsic value $1.12 per share, market price $0.75, margin of safety 33.1% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $1.12; the price of $0.75 is 33% below that value.

ETFs with the most weight in IBIO

More on IBIO

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than IBIO in Biotechnology

11 more in this industry show a wider margin of safety.

Is IBIO undervalued or overvalued?

IBIO is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $1.12; the price of $0.75 is 33% below that value.

What is the intrinsic value of IBIO?

$1.12 per share (as of the 2026-11-17 close), against a market price of $0.75. That is a margin of safety of 33.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.